A cutting-edge mouse study reveals that tirzepatide, the dual GLP-1/GIP drug already hailed for impressive weight loss, does more than trim fat: it slashes the growth of obesity-linked breast tumors.

In a striking new study, the anti-obesity drug tirzepatide, known as Mounjaro and Zepbound, not only triggered significant ...

The anti-obesity medication tirzepatide, marketed as Mounjaro for diabetes and Zepbound for obesity, reduced ...

Popular anti-obesity medications continue to be effective for weight loss even when availability and access is interrupted, ...

Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay ...

The anti-obesity medication tirzepatide, marketed as Mounjaro for diabetes and Zepbound for obesity, reduced obesity-associated breast ...

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

Women and older adults taking the anti-obesity drug semaglutide may be at higher risk for muscle loss, but higher protein ...

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

Insurers are cutting coverage, citing costs. But there’s seldom any discussion of the return on investment from these drugs ...

Multimodal AOMs were associated with the highest preoperative weight loss among patients with high BMI undergoing bariatric surgery.

Danish pharmaceutical giant Novo Nordisk is set to lose Canadian patent protection on its popular semaglutide-based drugs, ...